MAG and demyelinating disease: It was demonstrated that one of the most drastically reduced proteins in the brains of Gpr37/Gpr37L1 double knockout mice was the myelin-associated glycoprotein MAG, suggesting that GPR37 may be a potential drug target for the treatment of demyelinating diseases such as multiple sclerosis.